The Centers for Disease Control and Prevention (CDC) has issued recommendations advising against the use of rifampin and pyrazinamide in persons with latent tuberculosis infections (LTBI).
Precise data collected since January 2000 found high rates of hospitalization and death from liver injury associated with the combined use of rifampin and pyrazinamide.
Although the recommendations apply mainly to adults, treatment of some adolescents also may be affected. The combination of rifampin and pyrazinamide is not recommended for the treatment of LTBI in children.
“Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infections” (